Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$94.37 USD

94.37
743,349

-1.13 (-1.18%)

Updated Aug 8, 2025 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply

by Zacks Equity Research

Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.

Zacks Equity Research

Abbott Stock Down on Urgent Field Safety Notice for TactiCath

by Zacks Equity Research

Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.

Zacks Equity Research

LabCorp's New Website Offers Patients Coronavirus Trial Details

by Zacks Equity Research

LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.

Sreoshi Bera headshot

Digital Transformation Stocks to Stay Hot in 2020: 5 Picks

by Sreoshi Bera

The coronavirus pandemic has forced businesses to make digital transformations. As automation holds the key, these five stocks are poised to rally further.

Zacks Equity Research

Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt

by Zacks Equity Research

Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.

Zacks Equity Research

Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.

Zacks Equity Research

Why Is Illumina (ILMN) Up 13.8% Since Last Earnings Report?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

VRTX vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.

Zacks Equity Research

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

by Zacks Equity Research

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

Zacks Equity Research

Illumina (ILMN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 30.16% and 0.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Illumina (ILMN) Might Surprise This Earnings Season

by Zacks Equity Research

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.

Zacks Equity Research

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Earnings Preview: Illumina (ILMN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View

by Zacks Equity Research

Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.

Sweta Killa headshot

10 Stocks Leading the Rally in the S&P 500 ETF

by Sweta Killa

Signs of a slowdown in the number of hospitalizations and intensive-care admissions in New York and Europe has led to optimism over the reopening of the economy soon and improving activity in the near future.

Zacks Equity Research

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina (ILMN) Stock Moves -1.75%: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan